August 22, 2005
-
mmm. maybe i’ll be able to afford to move after all.
what fantastic news for diabetics (and investors.
)http://finance.yahoo.com/q?s=AMLN
If i have kids one day, they shall be named either LARs or LARa. haha!
http://yahoo.reuters.com/financeQuoteCompanyNewsArticle.jhtml?duid=mtfh41880_2005-08-22_22-17-55_n22496117_newsml
A quote from one of the articles:
“A1C, a measure of glucose control, improved approximately 2
percent for subjects receiving the high dose of exenatide LAR,
compared to placebo. At the beginning of the study, the average A1C of
study participants was approximately 8.5 percent. The decrease in A1C
was progressive with no evidence of a plateau at week 15. Twelve of
the 14 high-dose subjects who entered the study with an A1C greater
than 7 percent achieved an A1C of 7 percent or less at 15 weeks. None
of the 14 subjects receiving placebo achieved that target. The
American Diabetes Association recommends a target A1C of less than 7
percent.”8.5 percent a1c to under 7 percent? To me that sounds like 2 percentage points, not 2 percent.
Comments (4)
I hate to be a stick in the mud but the fiscal solvency of biotech companies is very depressing. I think Amylin is a wonderful interesting company but it’s been unable to earn a profit for the last five years. In fact when you examine their operating statements for each of the last five years they’ve been entirely financing their activities by issuing stock and taking on long term debt. This is very typical of the biotech market and I think that the long term strategy for most of these companies consists of waiting to be bought by larger pharmaceutical firms. Strangely this seems to have no effect on their stock prices. Right now. Sigh.
http://www.sharebuilder.com/sharebuilder/Research/StockDetail.asp?Mode=ANNUALINCOME&Symbol=AMLN&Tab=Financials
Rick Quickly
While you are correct on their numbers, it is because they were just approved by the FDA for their first drugs in their pipeline this year. I only minored in econ, so maybe i’m looking at this from such a simple standpoint, but if you aren’t seeling anything, it is tough to generate revenue.
http://amylin.com/pipeline/
Now it has two drugs (symlin for type 1s and byetta for type 2s) which are first-in-class drugs. Symlin (pramlinitide) has been shown in studies to not only improve glycemic control, but also bring down body weight. Byetta (exenatide) in its LAR form (Long Acting Release) will eliminate the need for daily injections. Multiple injections or once a week…..its a tough choice. Oh, and there are also exenatide studies which are going on in which beta cell islet regeneration is stimulated…..
Oh, and the prescription numbers for each of these drugs are growing faster than expected (i’ve seen the reports for these) and the Amylin sales team isn’t even out in full-force yet.
sheesh, maybe i should be a sales rep for them.
Neat link !!! My comments were rooted in the bitterness of the internet stock crash. I’m too jaded.
You know seriously, the whole drug sales rep thing actually has potential. Especially if it’s a new product that you’ve spent a fair amount of time studying. People who can bring a fair amount of analytical talent to sales often wind up in the upper levels of management … nothing to sneeze at.
very true. i got burned by altavista (cmgi) when i thought it’d be a good investment after i spent the summer working there. 20 to 175 to pretty much 0. not much, but a years ira down the drain…..
i’m sure there will be a sell-off, but whats interesting about this stock price is that there are 25 million shares out there which have been shorted, they have to buy back and cover eventually….